SAB Biotherapeutics Strengthens Board of Directors with Appointment of Biotech Veteran
26.4.2017 16:00 | Business Wire
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company, today announced that Thorkil Kastberg Christensen has joined their Board of Directors. SAB, which was founded in 2014, develops human antibody therapeutics using its first-of-its-kind immunotherapy platform.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170426006134/en/
Thorkil Kastberg Christensen (Photo provided by Thorkil K. Christensen)
Christensen brings to SAB decades of global business strategy and execution as former Chief Financial Officer of Denmark-based Novo A/S, which invests and manages the assets of the Novo Nordisk Foundation valued at about US$40 billion. He also established Novo Nordisk organizations around the world over two decades–as CEO of China and Vice President of International Operations.
“SAB’s technology is a platform for development of better and more effective medicines in many areas with unmet needs,” said Thorkil Kastberg Christensen. “This is at the heart of what I have been doing most of my life and I am happy to be able contribute,” he added.
Currently, Christensen serves as advisor for Novo A/S and a professional board member for Strategic Design Group and Sonion A/S among others. Since 2009, he has held additional board positions with private and publicly listed companies, in Denmark, abroad, and in public institutions including Chairman of the board of Danish-Chinese Business Forum, Jørgen Kruuse A/S and BioMimetics Inc., USA.
For SAB, Christensen has served as a strategic international business advisor since July of 2015.
“Mr. Christensen has been a trusted advisor and asset to SAB as we have advanced our technology and expanded collaborations within the U.S. and globally,” said Eddie Sullivan, Ph.D., president and CEO of SAB Biotherapeutics.
“His experience with financing, technology deployment and his network with leading public health, biotech and Pharma organizations will be valuable to the board as we continue to build our footprint and portfolio,” he added.
As a proven leader in life science business, Christensen has specialized in internationalization, as well as mergers, acquisitions, and other transactions. This work includes building organizations, transforming companies from R&D to commercial focus, and adding value to growing companies.
“The possibilities for using human antibodies, and polyclonals in particular, for the benefit of mankind are endless and in many areas there are great commercial potentials as well,” said Christensen. “I look forward to working closer with the colleagues at SAB in striving to realize some of these potentials.”
SAB is developing products for several targets including seasonal influenza, mycoplasma, C-Diff, Zika and Ebola. In addition, a Phase I Clinical Trial with the National Institutes of Health for its treatment for MERS-CoV is nearly complete and has funding support from BARDA for Phase 2.
In 2016 SAB’s novel immunotherapy platform was recognized by the World Health Organization as the most promising therapeutic platform technology to combat priority pathogens as well as other diseases with epidemic potential.
“With the unique capability of our technology platform in its ability to rapidly respond to various life-threatening diseases, our business is a global one,” added Sullivan. “Leveraging Mr. Christensen’s experience and expertise will only strengthen our capability to bring life-saving therapies to people in countries around the world.”
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical stage, biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced polyclonal antibody science in the world, SAB is delivering the world’s first large-scale platform to create fully human immunoglobulins. This natural production platform holds the potential for treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.
SAB Biotherapeutics, Inc.
Melissa Ullerich, +1 605-695-8350
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
The Valence Group Issues Fairness Opinion to SK Capital in Connection with Archroma18.8.2017 13:30 | Pressemelding
The Valence Group has provided a fairness opinion to SK Capital Partners, LP in connection with its recapitalization of Archroma, including investments made by various affiliates of SK Capital. Terms of the transaction were not disclosed. About SK Capital SK Capital is a private investment firm focused on the specialty materials, chemicals and pharmaceutical sectors. The firm builds strong and growing businesses that generate substantial long-term value for its investors. SK Capital utilizes its industry, operating and investment experience to identify opportunities to transform businesses into higher performing companies with improved strategic positioning, growth, profitability and risk profiles. The firm currently has approximately $1.9 billion of assets under management and its portfolio companies generate revenues of over $5.0 billion annually and employ approximat
Biker Summer 2017 campaign: What’s happening during Biker Summer 2017? Moto-tyres.co.uk is giving away exciting prizes!18.8.2017 09:22 | Pressemelding
Whether it’s a short weekend break or a long-distance tour – once again this year Moto-tyres.co.uk is asking bikers from 10 countries about their dream destinations and longest journeys as part of its “Biker Summer 2017” campaign. To ensure than nothing gets in the way of your next tour, the two-wheeler tyre store from Delticom, Europe’s leading online tyre dealer, is entering anyone who completes the survey before 30 September 2017 into a prize draw to win some great biking accessories. Simply answer three short questions about your plans for bike tours this year (don’t forget to provide your name and email address), and with a bit of luck, you might win one of these great prizes. Up for grabs are a GARMIN motorbike GPS system, a GoPro camera with helmet bracket and five 200-Pound vouchers for new motorbike tyres from the online store – thanks to the product range at Moto-tyres.co.uk, eve
Lenovo Continues to Gain Momentum in First Quarter FY 2017/1818.8.2017 00:04 | Pressemelding
Behind the strength of its 3-wave strategy, Lenovo’s business transformation continued to gain traction during the first quarter, delivering solid profitability in its core PC and smart devices business, and revenue and profit improvements in targeted growth areas, including the data center and mobile businesses. Fueled by new investments in people and products, Lenovo’s Data Center Group (DCG) introduced the most comprehensive product lineup in its history, with the new ThinkSystem and ThinkAgile portfolio, and continued to build out its end-to-end sales organization. Similarly, Lenovo’s Mobile Business Group launched significant new products led by the Moto Z2 Force, available now on all major U.S. carriers, and ramped up its branding efforts worldwide. “In the first quarter this fiscal year, we had stable performance as we executed our 3-wave strategy with commitment. We
Spirent Tests Wi-Fi Network Performance with O2 at the Coca-Cola London Eye17.8.2017 15:57 | Pressemelding
Spirent Communications plc (LSE:SPT), today announced its Landslide E10 network test platform has been used with O2 to validate the Wi-Fi network performance and capacity at the Coca-Cola London Eye, before the launch of a new smartphone application last month. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170817005758/en/ Spirent Landslide E10 helped O2 validate Wi-Fi performance and capacity at the Coca-Cola London Eye, before the launch of a new smartphone application last month. (Photo: Busines Wire) Merlin Entertainments plc, operator of the London Eye, wanted to measure its Wi-Fi network performance, to ensure its infrastructure could provide an excellent experience for users of the new app, which puts increased demands on the Wi-Fi network. “The London Eye is a global attractio
Watch BizWireTV: A Camera You Can Wear and Krispy Kreme’s Famous Donuts Get Eclipsed with Chocolate17.8.2017 12:08 | Pressemelding
On BizWireTV, catch some Quick Biz Hits and see the latest in Star Power. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170817005305/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Top of the Wire Introducing FrontRow: the camera re-invented. Watch BizWireTV to see more disruptors as well as the top 5 trending stories of the week! A core c
PsiOxus Therapeutics Announce Two New Board Appointments: New Board Appointments Strengthen Company’s US Presence17.8.2017 07:00 | Pressemelding
PsiOxus Therapeutics, Ltd. (PsiOxus) today announced the appointment of Charles Rowland and Duncan Higgons to the Board of Directors as part of an ongoing drive to expand in the US. Charles Rowland was most recently the President and Chief Executive Officer (CEO) of Aurinia Pharmaceuticals, a clinical stage pharmaceutical company focused on the global lupus nephritis market. Prior to this, he served as the Vice President and Chief Financial Officer (CFO) of ViroPharma, during which time the company grew into a global biopharmaceutical business with $500 million in annual revenues until it was acquired by Shire plc for $4.2 billion. Before joining ViroPharma, Mr. Rowland was executive Vice President, CFO, and interim co-CEO, for Endo Pharmaceuticals. In his earlier career, Charles held finance and operational positions at Biovail Pharmaceuticals, Breakaway Technologies, Pharmacia
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom